Title

Heart of Glass - Blenko Glass

Blenko Glass is a West Virginia treasure that spans generations. Nothing symbolizes the state of West Virginia better or more beautifully than Blenko Glass. We will discuss current and former craftsmen and designers and how important it is that Blenko and West Virginia glass be appreciated and valued by the younger generation.

Wednesday, November 01, 2017

PURPLE - Is the Color for Pancreatic Cancer. November is Pancreatic Cancer Month


Each year during the Breast Cancer Awareness month,  Pancreatic Cancer Awareness month, Blood Cancer Awareness  month we ask that you consider donating to the national organizations.    I also suggest using a BLENKO GLASS container in the chosen color - ie red for blood cancer, pink for breast cancer and PURPLE for Pancreatic Cancer -  you may refill the vase with flowers when you visit or perhaps a bowl that you refill with fruit.   
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. There are a number of types of pancreatic cancer.The most common, pancreatic adenocarcinoma, accounts for about 85% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type.These adenocarcinomas start within the part of the pancreas which makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the non-adenocarcinomas, can also arise from these cells. One to two percent of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas.These are generally less aggressive than pancreatic adenocarcinoma.
Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine and loss of appetite. There are usually no symptoms in the disease's early stages, and symptoms that are specific enough to suggest pancreatic cancer typically do not develop until the disease has reached an advanced stage. By the time of diagnosis, pancreatic cancer has often spread to other parts of the body.
Pancreatic cancer rarely occurs before the age of 40, and more than half of cases of pancreatic adenocarcinoma occur in those over 70. Risk factors for pancreatic cancer include tobacco smoking, obesity, diabetes, and certain rare genetic conditions. About 25% of cases are linked to smoking,and 5–10% are linked to inherited genes. Pancreatic cancer is usually diagnosed by a combination of medical imaging techniques such as ultrasound or computed tomography, blood tests, and examination of tissue samples (biopsy). The disease is divided into stages, from early (stage I) to late (stage IV). Screening the general population has not been found to be effective.
The risk of developing pancreatic cancer is lower among non-smokers, and people who maintain a healthy weight and limit their consumption of red or processed meat. A smoker's chance of developing the disease decreases if they stop smoking, and almost returns to that of the rest of the population after 20 years. Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy, palliative care, or a combination of these.  Treatment options are partly based on the cancer stage.  Surgery is the only treatment that can cure pancreatic adenocarcinoma, and may also be done to improve quality of life without the potential for cure.  Pain management and medications to improve digestion are sometimes needed.   Early palliative care is recommended even for those receiving treatment that aims for a cure.
In 2015, pancreatic cancers of all types resulted in 411,600 deaths globally   Pancreatic cancer is the fifth most common cause of death from cancer in the United Kingdom, and the fourth most common in the United States.  The disease occurs most often in the developed world, where about 70% of the new cases in 2012 originated.   Pancreatic adenocarcinoma typically has a very poor prognosis: after diagnosis, 25% of people survive one year and 5% live for five years.  For cancers diagnosed early, the five-year survival rate rises to about 20%.  Neuroendocrine cancers have better outcomes; at five years from diagnosis, 65% of those diagnosed are living, though survival varies considerably depending on the type of tumor.  **  Thank you to blog reader Amy G. for this info from wiki and other internet sites.


No comments: